dr-michelle-hermiston-md-104-1440x784-2x
Michelle L. Hermiston

Michelle L. Hermiston

MD, PhD

Pediatric hematologist-oncologist
Bone marrow transplant specialist
Director, Pediatric Immunotherapy Program
Runner and camper

Contact me

Contact me

Dr. Michelle L. Hermiston is a specialist in caring for children with blood diseases, including cancers of the blood. In research, she has a special interest in defining the underlying mechanisms in the development of lymphoid malignancies, including leukemia and lymphoma.

Hermiston earned her medical degree and a doctorate in developmental biology at Washington State University. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at UCSF before joining the faculty in 2002. She also participated in a medical scientist training program at Washington University and in the UCSF Molecular Medicine Research Fellowship Program.

Hermiston is a member of numerous professional organizations, including the American Society of Hematology and American Academy of Pediatrics.

  • Board Certifications

    American Board of Pediatrics, Pediatric Hematology-Oncology, 2004

  • Fellowships

    UCSF, Ped. Hema/Oncology, 2002

  • Residencies

    UCSF, Pediatrics, 1999

  • Internship

    UCSF, Pediatrics, 1998

  • Degree

    Washington State University, 1997

  • Languages

    English

"It feels like such a privilege to get to do this."

Meet Dr. Hermiston

Where I see patients (3)

    Selected research

    See all research
    Decorative Caduceus

    Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm

    Recruiting

    More about this study
    Decorative Caduceus

    Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    Proportion of participants with (complete response, partial response, stable disease, progressive disease) by 1 year of therapy with Cobimetinib. It is assumed that at each protocol-specified timepoint, a response assessment occu...

    Recruiting

    More about this study
    Decorative Caduceus

    Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Mali...

    The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.

    Recruiting

    More about this study
    See all clinical trials

    My work

    Meet UCSF's first CAR T-cell patient

    Shaun had been battling an aggressive leukemia for six years. When Dr. Hermiston recommended a new experimental treatment, his parents described it as "divine intervention."

    Contact me

    Feeling at home

    From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.

    Visit Child Life services

    Share